16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML); colorectal cancer; brain cancer; sarcoma In silico and cell culture studies identified a small molecule mTORC1 inhibitor that could help treat CML, colorectal cancer, glioblastoma and osteosarcoma. Docking and molecular dynamics...
03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication. Sarcopenia...
21:00 , Aug 3, 2018 |  BC Extra  |  Company News

Management tracks: Cellectis, Navitor

Zafgen Inc. (NASDAQ:ZFGN) CEO Thomas Hughes has stepped down from the metabolic disease company to become CEO at Navitor Pharmaceuticals Inc. (Cambridge, Mass.). Zafgen is seeking a successor. In June, Navitor begin Phase I testing...
15:37 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

resTORbio forging ahead with anti-infective after Phase IIb readout

Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent respiratory tract infections showed that all three dose regimens of the candidate missed the study's primary endpoint vs....
20:57 , Jul 25, 2018 |  BC Extra  |  Clinical News

resTORbio forging ahead with anti-infective after Phase IIb readout

Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent respiratory tract infections showed that all three dose regimens of the candidate missed the study's primary endpoint vs....
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
18:21 , May 25, 2018 |  BC Week In Review  |  Company News

Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor (KPT-8602)...
22:16 , May 24, 2018 |  BC Extra  |  Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
18:21 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sam/ple and cell culture studies suggest inhibiting DEPTOR could help treat colorectal cancer. In samples of colorectal tumors and the surrounding mucosa from patients, DEPTOR expression was higher than in normal colon...
23:23 , May 4, 2018 |  BC Extra  |  Preclinical News

PPAR agonist-induced fatty acid metabolism boosts tissue regeneration

Scientists at the Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology published a paper in Cell Stem Cell showing that fatty acid oxidation (FAO) induced by short-term fasting promotes tissue regeneration and repair,...